SOSAFE
24.5.2023 08:01:30 CEST | Business Wire | Press release
SoSafe, Europe’s leading vendor for security awareness and training, today announced it has appointed two world-class cybersecurity industry leaders to its board: Tech executive Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, and Bhagwat Swaroop, experienced executive in the cybersecurity space and current President of Digital Security Solutions at Entrust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005033/en/
Europe’s leading security awareness and training vendor SoSafe adds Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, to their board. (Photo: Business Wire)
Niklas Hellemann, CEO of SoSafe: “At SoSafe, we are at the forefront of security awareness innovation. Bringing two world-class industry leaders like Zeynep and Bhagwat for our board will strengthen our market expertise even further, boosting international expansion and product excellence. Advances in generative AI will inevitably lead to an escalation of the cyber threat landscape, particularly from a human risk perspective. We are delighted to welcome two highly experienced cybersecurity experts to our board, helping us to navigate this paradigm shift. SoSafe’s whole management team is very much looking forward to working with them.”
Zeynep Inanoglu Ozdemir has held key marketing leadership roles at Palo Alto Networks during a four-year period of rapid growth and transformation. As CMO, she has been responsible for launching an award-winning brand campaign for the company as well as pioneering the XDR category in cybersecurity at large. Previously, Ozdemir has worked at Palantir Technologies and Google, and currently sits on the board at iKSV, Turkey’s predominant arts and culture foundation. She holds a PhD in speech processing from Cambridge University, Machine Intelligence Lab, and a bachelor's degree in electrical engineering from Harvard University. Her deep expertise in category creation, data-driven marketing and growth strategies will be of great value to our board at SoSafe.
“Human-level risk management and security awareness programs are key capabilities in an increasingly automated threat landscape”, says Ozdemir. “I am very excited work with SoSafe to further their mission to drive secure behavior at scale.”
Bhagwat Swaroop is the President of Digital Security Solutions at Entrust and brings more than 20 years of leadership experience driving growth in global high-tech companies to the board. He was most recently president and General Manager of One Identity, where he led the company’s turnaround to a cloud-based cybersecurity company. Prior to One Identity, Swaroop was a Corporate Officer and Executive Vice President at Proofpoint responsible for driving company’s rapid growth and helped make Proofpoint the market leader in email security. Previously he held leadership positions at Symantec, NetApp, McKinsey, and Intel. He is a seasoned strategic leader and brings a deep understanding of the enterprise security landscape, technology ecosystem and cloud driven business models. He is a sought expert and public speaker on cybersecurity, cloud computing and national policy topics. “Security awareness training has become a foundational capability to make the human layer more resilient to the constant phishing attempts.” states Swaroop. “I was impressed by SoSafe’s deep focus on fusing behavioral science with cybersecurity awareness solutions. I am looking forward to working with the SoSafe leadership team in the next phase of their growth journey”.
With these new additions to its board, European security awareness leader SoSafe underlines its commitment for international expansion and product innovation.
_______________
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 3000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: https://www.linkedin.com/company/sosafe-cyber-security/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom